1. EMA 2018. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU. https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some. Accessed February 23, 2023.
2. Health Canada 2022. Pfizer recalls Inderal-LA (propranolol hydrochloride) capsules due to a nitrosamine impurity. https://recalls-rappels.canada.ca/en/alert-recall/pfizer-recalls-inderal-propranolol-hydrochloride-capsules-due-nitrosamine-impurity. Accessed February 23, 2023.
3. EMA 2021. CHAMPIX (varenicline) - lots to be recalled due to presence of impurity N-nitroso-varenicline. https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-champix-varenicline-lots-be-recalled-due-presence_en.pdf. Accessed April 13, 2023.
4. FDA 2021. Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX® (Varenicline) Tablets Due to N-Nitroso Varenicline Content. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pfizer-expands-voluntary-nationwide-recall-include-all-lots-chantixr-varenicline-tablets-due-n. Accessed April 13, 2023.
5. EMA 2020. Suspension of ranitidine medicines in the EU. https://www.ema.europa.eu/en/documents/press-release/suspension-ranitidine-medicines-eu_en.pdf. Accessed February 23, 2023.